Filtered By:
Condition: Arthritis
Therapy: Corticosteroid Therapy
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 25 results found since Jan 2013.
Association between Anti-inflammatory Drug and Dementia in Patients with Gout: A Nationwide, Population-Based Nested Case-Control Study
Conclusion: We had identified that > 90-day corticosteroid administration is a significant dementia risk factor in both female and male patients of all ages, especially in the 50-60-year-old group.PMID:33850475 | PMC:PMC8040399 | DOI:10.7150/ijms.55496
Source: International Journal of Medical Sciences - April 14, 2021 Category: Biomedical Science Authors: Natalia Mikhailichenko Yu-Hsun Wang James Cheng-Chung Wei Te-Jen Lai Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
The Effectiveness of Ultrasound-Guided Subacromial-Subdeltoid Bursa Combined With Long Head of the Biceps Tendon Sheath Corticosteroid Injection for Hemiplegic Shoulder Pain: A Randomized Controlled Trial
ConclusionThe combination of SASD bursa and LHBT sheath corticosteroid injection is superior to SASD bursa injection alone in reducing shoulder pain and improving functional activities in patients with HSP.Clinical Trial Registrationwww.chictr.org.cn, Unique identifier: ChiCTR2100047125.
Source: Frontiers in Neurology - June 14, 2022 Category: Neurology Source Type: research
Intracranial rheumatoid nodule causing recurrent transient neurological deficits
Pract Neurol. 2022 Oct 5:pn-2022-003489. doi: 10.1136/pn-2022-003489. Online ahead of print.ABSTRACTA 67-year-old man with rheumatoid arthritis developed recurrent acute onset of stereotyped focal neurological abnormalities. Cerebral imaging showed a mass lesion in the left parieto-occipital lobe. Imaging did not show the time evolution expected in stroke and so he underwent an extensive workup, which was inconclusive. Brain biopsy identified a rheumatoid nodule causing an extensive inflammatory reaction that mimicked a mass. Following treatment with intravenous corticosteroids and rituximab infusions, his clinical conditi...
Source: Practical Neurology - October 5, 2022 Category: Neurology Authors: Natalie Brossard-Barbosa Laura Donaldson Elena Sokolova Laila AlShafai Edward Margolin Source Type: research
ATP-binding cassette G1 membrane transporter-mediated cholesterol efflux capacity influences coronary atherosclerosis and cardiovascular risk in Rheumatoid Arthritis
CONCLUSION: ABCG1-CEC inversely associated with plaque burden and vulnerability, and plaque progression conditionally on cumulative inflammation and corticosteroid dose. ABCG1-CEC inversely associated with events specifically in patients with noncalcified plaques, lower inflammation and in prednisone users.PMID:36996698 | DOI:10.1016/j.jaut.2023.103029
Source: Journal of Autoimmunity - March 30, 2023 Category: Allergy & Immunology Authors: George A Karpouzas Bianca Papotti Sarah R Ormseth Marcella Palumbo Elizabeth Hernandez Maria Pia Adorni Francesca Zimetti Matthew J Budoff Nicoletta Ronda Source Type: research
Inflammation and immunomodulatory therapies influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis
CONCLUSION: ABCA1-CEC associated with decreased atherosclerosis in patients with below-median baseline and time-averaged CRP and bDMARD use. Conversely, ABCA1-CEC associated with increased plaque in those with higher CRP, corticosteroid users, methotrexate nonusers, and bDMARD nonusers. While in well-treated and controlled disease ABCA1-CEC appears atheroprotective, in uncontrolled RA its action may be masked or fail to counteract the inflammation-driven proatherogenic state.PMID:37520890 | PMC:PMC10371792 | DOI:10.1016/j.jtauto.2023.100209
Source: Atherosclerosis - July 31, 2023 Category: Cardiology Authors: George A Karpouzas Bianca Papotti Sarah R Ormseth Marcella Palumbo Elizabeth Hernandez Maria Pia Adorni Francesca Zimetti Matthew J Budoff Nicoletta Ronda Source Type: research
